
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL		Application Number 10/675,971		1			
		Filing Date	October 2, 2003		2003		
FUKINI CA		First Named Inven	tor	Peter DiBe	enedetto		
MAR 2 8	2000	Art Unit		3738	,		
(to be used for all expespondence	e aftershitial filing)	Examiner Name		Not Yet As	ssigned		
Total Number of Pages in This Su	polission	Attorney Docket N	umber	5118			
ENCLOSURES (check all that apply)							
Fee Transmittal Form	☐ Drawing(s			After Alle	owance Communication to TC		
Fee Attached	Licensing	-related Papers			Communication to Board als and Interferences		
Amendment / Reply	Petition			Appeal (Communication to TC Notice, Brief, Reply Brief)		
After Final		Convert to a all Application		Proprieta	ary Information		
Affidavits/declaration(s)		Attorney, Revocation of Correspondence Add	lress	Status L	etter		
Extension of Time Request		☐ Terminal Disclaimer			nclosure(s) lentify below):		
Express Abandonment Requ	est	Request for Refund CD, Number of CD(s)					
Information Disclosure State							
Certified Copy of Priority Document(s)		Form 1449					
Reply to Missing Parts/		Copies of 15 References Copy of International Search Report Postcard					
Incomplete Application Reply to Missing Parts	•	, rostcard					
under 37 CFR1.52 or 1.5	53						
	SIGNATURE OF	APPLICANT, ATTOI	RNEY, OF	R AGENT			
Firm		GENZYME CORPORATION					
Signature		geober					
Printed Name Robert J. Cob		rt ·					
Date 24 Mars		L 05 Reg. No. 36,108					
	CERTIFICA	TE OF TRANSMISS	ION/MAI	LING			
I hereby certify that this corresp Service with sufficient postage Alexandria, VA 22313-1450 on the	as first class mail i	simile transmitted to the simile an envelope addres	ne USPTO ssed to: C	or deposited ommissioner	with the United States Postal for Patents, P.O. Box 1450,		
Signature (Caral S	Celata	> .				
Typed or printed name Ca	ol S. Celata			Date	3/04/2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicant submits form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-15

Certain of the listed references were cited in the International Search Report dated December 27, 2004 issued in the corresponding PCT application (copy attached herewith).

Applicant believes that no fee is due with this submission.

However, if any fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.

Respectfully submitted,

Robert J. Cobert

Attorney for Applicant Registration No. 36,108

GENZYME CORPORATION Legal Department 500 Kendall Street Cambridge, Massachusetts 02142 Tel. (617) 768-6823

Fax. (617) 252-7553

Date: -March 24, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

5.5. Faterit and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 144		Complete if Known				
				Application Number	10/675,971	
INFO	RMATION	DIS	CLOSURE	Filing Date	October 2, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Peter DiBenedetto			
				Art Unit	3738	
	(Use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	5118	

	U.S. PATENT DOCUMENTS						
Examiner Cite No.1		e Document Number 1 Number - Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant		
				Cited Document	Passages or Relevant Figures Appear		
	1	US-5,326,357	07/05/1994	Kandel			
	2	US- 5,591,740	01/07/1997	Chipman et al.			
	3	US- 2004/0203072	10/14/2004	Sandell et al.			
_		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
-	Ī	US-					
	İ .	US-					
		US-					
	1	US-			11.1		

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
	4	WO03/062457	07/31/2003	Rush- Presbyterian- St. Luke's Medical Center			
	5	WO03/106705	12/24/2003	Millenium Biologix AG			
				-			
	<u> </u>						
						-	

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/675,971	
Filing Date	October 2, 2003	
First Named Inventor	Peter DiBenedetto	
Art Unit	3738	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	5118	

	٠	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	١,
Examiner Initials *	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
-	6	HASCALL et al., "The Effect of Serum on Biosynthesis of Proteoglycans by Bovine Articular Cartilage in Culture", Archives of Biochemistry and Biophysics, Vol. 224, No. 1 pp. 206-223 (1983)	
	7	AYDELOTTE, et al. "Articular Chondrocytes Cultured in Agarose Gel for Study of Chondrocytic Chondrolysis", Articular Cartilage Biochemistry, pp. 235-256 (1986)	
	8	MUIR, et al., "Effects of Tiaprofenic Acid and Other NSAIDs on Proteoglycan Metabolism in Articular Cartilage Explants", <i>Drugs</i> , Vol. 35 (Suppl. 1), pp 15-23 (1988)	
	. 9	KOLIBAS et al., "Effect of cytokines and anti-arthritic drugs on glycosaminoglycan synthesis by bovine articular chondrocytes", <i>Agents and Actions</i> , Vol. 27, ¾ pp. 245-249 (1989)	
	10	ARSENIS et al., "Effects of antirheumatic drugs on the interleukin-1α induced synthesis and activation of proteinases in articular cartilage explants in culture", <i>Agents and Actions</i> , Vol. 27, ¾ pp. 261-264 (1989)	
	11	GUO et al., "Culture and Growth Characteristics of Chondrocytes Encapsulated in Alginate Beads", Connective Tissue Research, Vol. 19, pp. 277-297 (1989)	
	12	BOYLE et al., "Characterization of proteoglycan accumulation during formation of cartilaginous tissue in vitro", Osteoarthritis and Cartilage, Vol. 3, pp. 117-125 (1995)	
	13	TUBO et al., "Articular Cartilage", Human Cell Culture, Vol. V, pp. 1-16 (2001)	
	14	ADCOCKS, et al., "Catechins from Green Tea (Camellia sinensis) Inhibit Bovine and Human Cartilage Proteoglycan and Type II Collagen Degradation in Vitro ^{1,2n} , Journal of Nutrition, Vol. 132, No. 3, pp. 341-346 (2002)	
	15	CURTIS et al., "The Effect of n3 (Omega-3) Polyunsaturated Fatty Acids on Degenerative Joint Disease", Agro Food Industry Hi-Tech, Vol.14, No. 3 pp. 22-25 (2003)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.